Key Developments: Osiris Therapeutics Inc (OSIR.OQ)

OSIR.OQ on NASDAQ Stock Exchange Global Market

19.50USD
12:11pm EDT
Change (% chg)

$-0.05 (-0.28%)
Prev Close
$19.56
Open
$19.53
Day's High
$19.71
Day's Low
$19.41
Volume
14,272
Avg. Vol
45,510
52-wk High
$20.70
52-wk Low
$11.87

Search Stocks

Latest Key Developments (Source: Significant Developments)

Osiris Therapeutics, Inc announces a strategic partnership with Stryker for Marketing Osiris' Viable Bone Matrix
Monday, 22 Dec 2014 04:30pm EST 

Osiris Therapeutics, Inc:Enters into an exclusive, worldwide partnership with Stryker Corporation for the commercialization and development of Osiris' viable bone matrix tissue form.This partnership strategically aligns one of Osiris' leading regenerative medicine technologies with Stryker's innovative medical device portfolio; the resulting synergies will maximize the market potential.Agreement provides Stryker with exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO(4).  Full Article

Osiris Therapeutics Inc and Arthrex announces an exclusive partnership for commercialization and development of Cartiform
Friday, 17 Oct 2014 08:00am EDT 

Osiris Therapeutics Inc:Enters into an exclusive commercial and development partnership for its cartilage product, Cartiform, with Arthrex, Inc.Arthrex is global medical device company and in new product development and medical education in orthopaedics and sports medicine, operating in over 90 countries throughout world.  Full Article

Osiris Therapeutics Inc updates on acquisition of Osiris' culture-expanded mesenchymal stem cell business
Wednesday, 9 Apr 2014 08:00am EDT 

Osiris Therapeutics Inc:On Oct. 2013 signed agreement with subsidiary of Mesoblast Ltd.For acquisition of Osiris' culture-expanded mesenchymal stem cell (ceMSC) business, including Prochymal.Transaction worth upto $100 mln in initial consideration and milestone payments as well as future royalties.On April 8, receipt of $15 mln cash payment for Prochymal.  Full Article

Osiris Therapeutics Inc confirms Lode Debrabandere as president and chief executive officer
Tuesday, 14 Jan 2014 08:00am EST 

Osiris Therapeutics Inc:Says its Board of Directors, at a Special Meeting held on Jan. 13, 2014, confirmed the nomination of Lode Debrabandere, as President and Chief Executive Officer of the company.  Full Article

Osiris Therapeutics Inc Announces Leadership Transition
Monday, 2 Dec 2013 04:30pm EST 

Osiris Therapeutics Inc:Says C. Randal Mills, PhD. will be stepping down as President and Chief Executive Officer of the company for personal reasons.Says Osiris` Chief Operating Officer, Lode Debrabandere, Ph.D., will assume the role of President and Chief Executive Officer pending Board confirmation.  Full Article

Osiris Therapeutics Inc Announces Agreement For Sale Of Culture-Expanded MSCs Including Prochymal Worth Up To $100 Million Plus Royalties To Mesoblast Ltd's Subsidiary
Thursday, 10 Oct 2013 07:12pm EDT 

Osiris Therapeutics Inc announced that it has entered into an agreement with a wholly owned subsidiary of Mesoblast Ltd for the sale of Osiris' culture-expanded mesenchymal stem cell (ceMSC) business, including Prochymal, in a transaction worth up to $100 million in initial consideration and milestone payments. Additionally, Osiris will receive royalty payments on sales of Prochymal and other products utilizing the acquired ceMSC technology. Summary of the Transaction: Mesoblast has acquired the assets related to Osiris` ceMSC business; Osiris will receive $50 million in consideration for closing and delivery of its ceMSC assets; Osiris is eligible to receive up to an additional $50 million in payments upon Mesoblast achieving certain clinical and regulatory milestones; Mesoblast will assume all future development costs for the ceMSC business; Osiris will receive single to low double-digit royalties on product sales derived from the ceMSC technology; Osiris and Mesoblast have entered into a separate services agreement for continued product advancement and to ensure a seamless transition; Osiris has retained a license to all transferred intellectual property necessary to run its other businesses; and For Osiris, the transaction results in pro forma cash, investments and receivables of approximately $82 million. Osiris expects to record the closing and asset transfer consideration of $51 million in the fourth quarter of fiscal 2013.  Full Article

Search Stocks